Values as of: 2024-10-30
COMMON STOCK | Biotechnology |
Last Closing
USD 97.095Change
-0.12 (-0.12)%Market Cap
USD 36.53BVolume
4.50KAnalyst Target
N/AVerdict
Verdict
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Company Website : https://www.ucb.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| UCBJF | UCB SA |
N/A |
USD 35.59B |
| ARGNF | argenx SE |
N/A |
USD 33.74B |
| GNMSF | Genmab A/S |
-2.12 (-0.95%) |
USD 14.31B |
| WXIBF | WuXi Biologics |
N/A |
USD 10.26B |
| IVBIY | IVBIY |
N/A |
USD 9.55B |
| WXXWY | WuXi Biologics (Cayman) Inc |
-0.16 (-3.69%) |
USD 9.11B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 8.66B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 8.61B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 8.60B |
| AKESF | Akeso, Inc. |
N/A |
USD 8.00B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| DRDR:LSE | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
+3.00 (+0.96%) |
N/A |
| HEAL:LSE | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
+0.08 (+0.96%) |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 122.69% | 75% | C | 86% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 122.69% | 75% | C | 86% | B+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 169.63% | 80% | B- | 88% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 169.63% | 80% | B- | 88% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 146.12% | 84% | B | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 146.12% | 84% | B | 87% | B+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 10.85% | 54% | F | 55% | F | ||
| Dividend Return | 12.52% | 55% | F | 53% | F | ||
| Total Return | 1.67% | 85% | B | 36% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 35.38% | 83% | B | 65% | D | ||
| Risk Adjusted Return | 35.38% | 87% | B+ | 72% | C | ||
| Market Capitalization | 36.53B | 100% | F | 97% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
